These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 22274144

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab.
    Mitchell P.
    Curr Med Res Opin; 2011 Jul; 27(7):1465-75. PubMed ID: 21623685
    [Abstract] [Full Text] [Related]

  • 26. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration.
    Emerson MV, Lauer AK, Flaxel CJ, Wilson DJ, Francis PJ, Stout JT, Emerson GG, Schlesinger TK, Nolte SK, Klein ML.
    Retina; 2007 Jul; 27(4):439-44. PubMed ID: 17420695
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Bevacizumab (AVASTIN) and age-related macular degeneration. Lower cost does not justify taking risks.
    Prescrire Int; 2015 Sep; 24(163):201-4. PubMed ID: 26417625
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Preferred therapies for neovascular age-related macular degeneration.
    Chiang A, Regillo CD.
    Curr Opin Ophthalmol; 2011 May; 22(3):199-204. PubMed ID: 21427571
    [Abstract] [Full Text] [Related]

  • 32. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
    Dunavoelgyi R, Sacu S, Eibenberger K, Palkovits S, Leydolt C, Pruente C, Schmidt-Erfurth U.
    Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
    [Abstract] [Full Text] [Related]

  • 33. Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis.
    Schmid MK, Bachmann LM, Fäs L, Kessels AG, Job OM, Thiel MA.
    Br J Ophthalmol; 2015 Feb; 99(2):141-6. PubMed ID: 25271911
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study.
    Moshfeghi AA, Rosenfeld PJ, Puliafito CA, Michels S, Marcus EN, Lenchus JD, Venkatraman AS.
    Ophthalmology; 2006 Nov; 113(11):2002.e1-12. PubMed ID: 17027972
    [Abstract] [Full Text] [Related]

  • 37. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).
    Stewart MW, Rosenfeld PJ, Penha FM, Wang F, Yehoshua Z, Bueno-Lopez E, Lopez PF.
    Retina; 2012 Mar; 32(3):434-57. PubMed ID: 22374154
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration: a retrospective study of 58 patients.
    De Bats F, Grange JD, Cornut PL, Feldman A, Burillon C, Denis P, Kodjikian L.
    J Fr Ophtalmol; 2012 Nov; 35(9):661-6. PubMed ID: 23040443
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.